683 Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-250,000
| Closed | -$10.1M | – | 160 |
|
|
2026
Q1 | $10.1M | Sell |
250,000
-80,000
| -24% | -$1.72M | 0.52% | 42 |
|
|
2025
Q4 | $8.29M | Buy |
330,000
+42,000
| +15% | +$985K | 0.36% | 55 |
|
|
2025
Q3 | $6.52M | Sell |
288,000
-122,000
| -30% | -$2.85M | 0.34% | 61 |
|
|
2025
Q2 | $7.1M | Buy |
410,000
+77,000
| +23% | +$1.43M | 0.47% | 56 |
|
|
2025
Q1 | $7.28M | Sell |
333,000
-27,000
| -8% | -$746K | 0.5% | 57 |
|
|
2024
Q4 | $11.5M | Buy |
360,000
+125,000
| +53% | +$3.76M | 0.71% | 35 |
|
|
2024
Q3 | $6.78M | Buy |
235,000
+49,000
| +26% | +$1.81M | 0.52% | 52 |
|
|
2024
Q2 | $7.13M | Sell |
186,000
-29,000
| -13% | -$1.31M | 0.54% | 49 |
|
|
2024
Q1 | $12.6M | Buy |
215,000
+85,000
| +65% | +$5.42M | 0.92% | 37 |
|
|
2023
Q4 | $7.78M | Sell |
130,000
-110,000
| -46% | -$5.58M | 0.64% | 53 |
|
|
2023
Q3 | $9.13M | Buy |
240,000
+195,700
| +442% | +$8.6M | 0.71% | 50 |
|
|
2023
Q2 | $4.04M | Sell |
44,300
-115,700
| -72% | -$9.98M | 0.29% | 76 |
|
|
2023
Q1 | $10.6M | Sell |
160,000
-15,000
| -9% | -$866K | 0.79% | 36 |
|
|
2022
Q4 | $9.05M | Buy |
+175,000
| New | +$9.28M | 0.77% | 41 |
|
Other funds holding APLS
683 Capital Management's APLS Position: Q2 2026 in Review
683 Capital Management sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 250,000 shares — an estimated $10.1M sold.
683 Capital Management first reported a position in APLS in Q4 2022 and held it in 14 quarters. The position peaked at $12.6M in Q1 2024. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- 683 Capital Management reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- 683 Capital Management sold 250,000 Apellis Pharmaceuticals shares in Q2 2026, an estimated $10.1M.
- 683 Capital Management first reported a position in Apellis Pharmaceuticals in Q4 2022 and held it in 14 quarters.
- 683 Capital Management's Apellis Pharmaceuticals position peaked at $12.6M in Q1 2024.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on 683 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.